Splenomegaly: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 639: | Line 639: | ||
* Close contact | * Close contact | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 676: | Line 676: | ||
* Close contact | * Close contact | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 973: | Line 973: | ||
|- | |- | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammation | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammation | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Sarcoidosis]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Sarcoidosis]]<ref name="pmid25473783">{{cite journal |vauthors=Modaresi Esfeh J, Culver D, Plesec T, John B |title=Clinical presentation and protocol for management of hepatic sarcoidosis |journal=Expert Rev Gastroenterol Hepatol |volume=9 |issue=3 |pages=349–58 |date=March 2015 |pmid=25473783 |doi=10.1586/17474124.2015.958468 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Immunity (medical)|Immune]] mediated | * [[Immunity (medical)|Immune]] mediated | ||
Line 987: | Line 987: | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Bilateral [[Hilar lymphadenopathy|hilar adenopathy]] | * Bilateral [[Hilar lymphadenopathy|hilar adenopathy]] | ||
Line 1,011: | Line 1,011: | ||
* Systemic [[Inflammation|inflammatory]]<nowiki/>disease | * Systemic [[Inflammation|inflammatory]]<nowiki/>disease | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Serum sickness]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Serum sickness]]<ref name="pmid26677148">{{cite journal |vauthors=Chiong FJ, Loewenthal M, Boyle M, Attia J |title=Serum sickness-like reaction after influenza vaccination |journal=BMJ Case Rep |volume=2015 |issue= |pages= |date=December 2015 |pmid=26677148 |pmc=4691861 |doi=10.1136/bcr-2015-211917 |url=}}</ref> | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Immune complex hypersensitivity (type III) to certain medications | |||
| align="center" style="background:#F5F5F5;" |Any | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Consumption of certain medications | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |+ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |+ | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Rashes | |||
* Itching | |||
* Facial swelling | |||
* Arthralgia | |||
* Lymphadenopathy | |||
* Dyspnea | |||
| align="center" style="background:#F5F5F5;" |↓ or ↑ | |||
Eosinophilia | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Proteinuria | |||
* Hematuria | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Plasma cells on peripheral blood smear | |||
* Numerous histological changes including inflammation of arterial wall or fibrosis | |||
| align="center" style="background:#F5F5F5;" |NA | |||
| align="center" style="background:#F5F5F5;" |Clinical manifestation + recent medication consumption | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Glomerulonephritis | |||
* Shock | |||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Systemic lupus erythematosus]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Systemic lupus erythematosus]]<ref name="pmid24461385">{{cite journal |vauthors=Yu C, Gershwin ME, Chang C |title=Diagnostic criteria for systemic lupus erythematosus: a critical review |journal=J. Autoimmun. |volume=48-49 |issue= |pages=10–3 |date=2014 |pmid=24461385 |doi=10.1016/j.jaut.2014.01.004 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Immune mediated [[Bone marrow suppression|bone marrow failure]] | * Immune mediated [[Bone marrow suppression|bone marrow failure]] | ||
Line 1,075: | Line 1,090: | ||
* Multi organ damage | * Multi organ damage | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Felty's syndrome|Felty syndrome]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Felty's syndrome|Felty syndrome]]<ref name="pmid24472276">{{cite journal |vauthors=Huang T, Liu M, Xu G |title=Felty's syndrome with hyperthyroidism: a case report and literature review |journal=Int J Rheum Dis |volume=17 |issue=1 |pages=122–4 |date=January 2014 |pmid=24472276 |doi=10.1111/1756-185X.12117 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Immune mediated [[Bone marrow suppression|bone marrow failure]] | * Immune mediated [[Bone marrow suppression|bone marrow failure]] | ||
Line 1,170: | Line 1,185: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Niemann-Pick disease]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Niemann-Pick disease]]<ref name="pmid23622394">{{cite journal |vauthors=Vanier MT |title=Niemann-Pick diseases |journal=Handb Clin Neurol |volume=113 |issue= |pages=1717–21 |date=2013 |pmid=23622394 |doi=10.1016/B978-0-444-59565-2.00041-1 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,197: | Line 1,212: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Amyloidosis]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Amyloidosis]]<ref name="pmid26230754">{{cite journal |vauthors=Czeyda-Pommersheim F, Hwang M, Chen SS, Strollo D, Fuhrman C, Bhalla S |title=Amyloidosis: Modern Cross-sectional Imaging |journal=Radiographics |volume=35 |issue=5 |pages=1381–92 |date=2015 |pmid=26230754 |doi=10.1148/rg.2015140179 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,224: | Line 1,239: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Langerhans cell histiocytosis]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Langerhans cell histiocytosis]]<ref name="pmid25281259">{{cite journal |vauthors=DiCaprio MR, Roberts TT |title=Diagnosis and management of langerhans cell histiocytosis |journal=J Am Acad Orthop Surg |volume=22 |issue=10 |pages=643–52 |date=October 2014 |pmid=25281259 |doi=10.5435/JAAOS-22-10-643 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,251: | Line 1,266: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Hemophagocytic lymphohistiocytosis]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Hemophagocytic lymphohistiocytosis]]<ref name="pmid26461149">{{cite journal |vauthors=Filipovich AH, Chandrakasan S |title=Pathogenesis of Hemophagocytic Lymphohistiocytosis |journal=Hematol. Oncol. Clin. North Am. |volume=29 |issue=5 |pages=895–902 |date=October 2015 |pmid=26461149 |doi=10.1016/j.hoc.2015.06.007 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,278: | Line 1,293: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Rosai Dorfman disease|Rosai-Dorfman disease]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Rosai Dorfman disease|Rosai-Dorfman disease]]<ref name="pmid23818241">{{cite journal |vauthors=Hashimoto K, Kariya S, Onoda T, Ooue T, Yamashita Y, Naka K, Okano M, Nishizaki K |title=Rosai-Dorfman disease with extranodal involvement |journal=Laryngoscope |volume=124 |issue=3 |pages=701–4 |date=March 2014 |pmid=23818241 |doi=10.1002/lary.24290 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,306: | Line 1,321: | ||
|- | |- | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hematologic (hypersplenic) states | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hematologic (hypersplenic) states | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Hemolytic anemia]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Hemolytic anemia]]<ref name="pmid26447931">{{cite journal |vauthors=Hill QA |title=Autoimmune hemolytic anemia |journal=Hematology |volume=20 |issue=9 |pages=553–4 |date=October 2015 |pmid=26447931 |doi=10.1179/1024533215Z.000000000401 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,333: | Line 1,348: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Sickle-cell disease|Sickle cell disease]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Sickle-cell disease|Sickle cell disease]]<ref name="pmid25390134">{{cite journal |vauthors=Gravitz L, Pincock S |title=Sickle-cell disease |journal=Nature |volume=515 |issue=7526 |pages=S1 |date=November 2014 |pmid=25390134 |doi=10.1038/515S1a |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,360: | Line 1,375: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Granulocyte colony-stimulating factor]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Granulocyte colony-stimulating factor]]<ref name="pmid23419039">{{cite journal |vauthors=Abraham I, Tharmarajah S, MacDonald K |title=Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors |journal=Expert Opin Drug Saf |volume=12 |issue=2 |pages=235–46 |date=March 2013 |pmid=23419039 |doi=10.1517/14740338.2013.770472 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | |
Revision as of 16:47, 4 October 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2], Gichoya Judy Wawira [3],
Synonyms and keywords: Spleen enlargement; enlarged spleen; spleen swelling
Differentiating Splenomegaly from Other Diseases
Category | Disease | Etiology | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | History | Symptoms | Signs | Lab Findings | Imaging | ||||||||||||||||||||||
Fever | Fatigue | Weight | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | CBC | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | |||||||||||
WBC | Hb | Plt | |||||||||||||||||||||||||
Congestive | Cirrhosis[1] | Any, more in elderly | – | + | ↑↓ | + | + | ↓ | Nl | + | + | ↓ | ↓ | ↓ | Nl | ↑ | ↑ | ↑ |
|
|
|
Liver biopsy | |||||
Heart failure[2] | Elderly |
|
– | + | ↑↓ | – | – | ↑ | ↑ | ± | + | ↓ | ↓ | ↑ | Nl | ↑ | ↑ | ↑ | Nl | NA |
|
Echocardiography |
| ||||
Thrombosis of portal, hepatic, or splenic veins[3] | Any | + | + | ↑ | + | + | ↓ | Nl | ± | + | ↓ | ↓ | ↓ | Nl | ↑ | ↑ | ↑ |
|
NA |
|
Doppler ultrasonography | ||||||
Malignancy | Lymphoma[4] | Any, most common malignant splenic tumor |
|
+ | + | ↓ | + | + | Nl | Nl | + | – | ↓ | ↓ | ↓ | High ferritin | ↑ | ↑ | ↑ | Nl |
|
|
Lymph node biopsy | ||||
Leukemia[5] |
|
Elderly, male>female |
|
+ | + | ↓ | + | + | Nl | Nl | ± | + | ↓ | ↓ | ↓ | High ferritin | ↑ | ↑ | ↑ | Nl |
|
NA | Bone marrow examination + clinical manifestation |
| |||
Polycythemia Vera[6] |
|
Mean age >60 years old |
|
– | + | Nl | + | – | Nl | Nl | – | – |
|
Nl to ↑ | ↑ | Nl to ↑ | High ferritin | Nl | Nl | Nl | Nl |
|
NA | WHO criteria for PV | |||
Disease | Etiology | Demography | History | Fever | Fatigue | Weight loss | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings | ||
Multiple myeloma[7] | Any, more in adults |
|
+ | + | ↓ | + | + | Nl | Nl | + | – | ↓ | ↓ | ↓ | High ferritin | Nl | ↑ | ↑ |
|
Bone marrow examination |
| ||||||
Essential thrombocythemia[8] |
|
Mean age >60 years old, female > male |
|
± | + | Nl | + | + | Nl | Nl | – | – | ↑ | ↑ | ↑↑ | Nl | Nl | Nl | Nl | Nl |
|
|
Bone marrow biopsy | ||||
Primary myelofibrosis[9] |
|
Mean age >60 years old, male> female |
|
– | + | Nl | + | + | Nl | Nl | + | – | ↓ | ↓ | ↑/↓ | Low iron | Nl | ↑ | Nl |
|
Bone marrow biopsy |
| |||||
Primary splenic tumors[10] |
|
Very rare |
|
+ | + | ↓ | + | – | Nl | Nl | – | – |
|
↓ | ↓ | ↓ | Low iron, low ferritin | ↑ | ↑ | ↑ |
|
|
Biopsy |
| |||
Metastatic solid tumors[11] |
|
Any, more in adults |
|
+ | + | ↓ | + | + | ↓ | Nl | ± | ± | ↓ | ↓ | ↓ | Low iron, high ferritin | ↑ | ↑ | ↑ |
|
Biopsy |
| |||||
Disease | Etiology | Demography | History | Fever | Fatigue | Weight | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings | ||
Infection | Viral | Hepatitis[12] |
|
Any |
|
+ | + | ↓ | + | + | Nl | Nl | + | + |
|
↓ | ↓ | ↓ | Nl | ↑ | ↑ | ↑ | Clinical manifestation + lab tests |
| |||
Infectious mononucleosis[13] |
|
More in children and young adults |
|
+ | + | Nl | + | – | Nl | Nl | + | – |
|
↑ | Nl | ↑ | Nl | ↑ | Nl | Nl | Nl | NA | Clinical manifestation + Heterophile antibody test |
| |||
Cytomegalovirus[14] |
|
More in immunocompromised patients and during pregnancy |
|
+ | + | Nl | + | – | Nl | Nl | + | – |
|
↑ | Nl | ↑ | Nl | ↑ | Nl | Nl | Nl | NA | ELISA | ||||
Bacterial | Salmonella[15] | ||||||||||||||||||||||||||
Brucella[16] | |||||||||||||||||||||||||||
Tuberculosis[17] | |||||||||||||||||||||||||||
Parasitic | Malaria[18] | ||||||||||||||||||||||||||
Schistosomiasis[19] | |||||||||||||||||||||||||||
Toxoplasmosis[20] | |||||||||||||||||||||||||||
Kala-azar[21] | Visceral leishmaniasis | ||||||||||||||||||||||||||
Infective endocarditis[22] | |||||||||||||||||||||||||||
Fungal[23] | |||||||||||||||||||||||||||
Disease | Etiology | Demography | History | Fever | Fatigue | Weight loss | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings | ||
Inflammation | Sarcoidosis[24] |
|
Autoimmune disease, more in young African American women |
|
+ | + | ↓ | + | + | Nl | Nl | – | – | ↑ | ↓ | ↑ | Nl | Nl | Nl | Nl | Nl | NA |
|
Diagnosis of exclusion |
| ||
Serum sickness[25] |
|
Any |
|
+ | + | Nl | + | – | ↓ | Nl | – | – |
|
↓ or ↑
Eosinophilia |
↓ | ↑ | Nl | Nl | Nl | ↑ |
|
|
NA | Clinical manifestation + recent medication consumption |
| ||
Systemic lupus erythematosus[26] |
|
More in young females |
|
+ | + | ↓ | + | + | Nl to ↓ | Nl | + | + | ↓ | ↓ | ↓ | ↑ | ↑ | ↑ |
|
Clinical findings + laboratory studies |
| ||||||
Felty syndrome[27] |
|
Rare autoimmune disease, more in females 50-70 years old |
|
+ | + | ↓ | + | + | Nl to ↓ | Nl | + | + |
|
↓ | ↓ | ↓ | Nl | Nl | Nl | Nl | Nl |
|
Clinical findings + laboratory studies | ||||
Infiltrative | Disease | Etiology | Demography | History | Fever | Fatigue | Weight loss | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings | |
Gaucher disease[28] |
|
Rare, mostly in children |
|
- | + | ↓ | + | + | Nl to ↓ | Nl | + | + | ↓ | ↓ | ↓ | Nl | Nl | ↑ | ↑ |
|
Clinical findings + laboratory studies | ||||||
Niemann-Pick disease[29] | |||||||||||||||||||||||||||
Amyloidosis[30] | |||||||||||||||||||||||||||
Langerhans cell histiocytosis[31] | |||||||||||||||||||||||||||
Hemophagocytic lymphohistiocytosis[32] | |||||||||||||||||||||||||||
Rosai-Dorfman disease[33] | |||||||||||||||||||||||||||
Hematologic (hypersplenic) states | Hemolytic anemia[34] | ||||||||||||||||||||||||||
Sickle cell disease[35] | |||||||||||||||||||||||||||
Granulocyte colony-stimulating factor[36] | |||||||||||||||||||||||||||
Disease | Etiology | Demography | History | Fever | Fatigue | Weight loss | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings |
References
- ↑ Wu Z, Zhou J, Pankaj P, Peng B (December 2012). "Laparoscopic and open splenectomy for splenomegaly secondary to liver cirrhosis: an evaluation of immunity". Surg Endosc. 26 (12): 3557–64. doi:10.1007/s00464-012-2366-5. PMID 22710653.
- ↑ Gedela M, Khan M, Jonsson O (September 2015). "Heart Failure". S D Med. 68 (9): 403–5, 407–9. PMID 26489162.
- ↑ Ferri PM, Ferreira AR, Fagundes ED, Liu SM, Roquete ML, Penna FJ (2012). "Portal vein thrombosis in children and adolescents: 20 years experience of a pediatric hepatology reference center". Arq Gastroenterol. 49 (1): 69–76. PMID 22481689.
- ↑ Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Abe O, Saito T, Tanaka Y (May 2015). "Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma". Hematology. 20 (4): 203–7. doi:10.1179/1607845414Y.0000000192. PMID 25131182.
- ↑ Quest GR, Johnston JB (December 2015). "Clinical features and diagnosis of hairy cell leukemia". Best Pract Res Clin Haematol. 28 (4): 180–92. doi:10.1016/j.beha.2015.10.017. PMID 26614896.
- ↑ Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH, Hong YC, Liu CY, Yang CF, Chen PM, Chiou TJ, Tzeng CH (March 2013). "Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage". Eur. J. Haematol. 90 (3): 228–36. doi:10.1111/ejh.12064. PMID 23281576.
- ↑ Grieco A, Manna R, Mancini R, Gambassi G (April 1988). "Massive hepatomegaly following splenectomy for myeloid metaplasia". Am. J. Med. 84 (4): 797. PMID 3400674.
- ↑ Tefferi A, Barbui T (February 2015). "Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management". Am. J. Hematol. 90 (2): 162–73. doi:10.1002/ajh.23895. PMID 25611051.
- ↑ Cervantes F, Martinez-Trillos A (May 2013). "Myelofibrosis: an update on current pharmacotherapy and future directions". Expert Opin Pharmacother. 14 (7): 873–84. doi:10.1517/14656566.2013.783019. PMID 23514013.
- ↑ Adachi K, Ui M, Nojima H, Takada Y, Enatsu K (August 2011). "Isolated splenic peliosis presenting with giant splenomegaly and severe coagulopathy". Am. J. Surg. 202 (2): e17–9. doi:10.1016/j.amjsurg.2010.10.002. PMID 21810495.
- ↑ Huprikar NA, Kurtz MT, Mount CA (October 2013). "Massive splenomegaly and lymphopenia: a unique case of obstructive shock". BMJ Case Rep. 2013. doi:10.1136/bcr-2013-201643. PMC 3822246. PMID 24172780.
- ↑ Kumar KJ, Kumar HC, Manjunath VG, Anitha C, Mamatha S (January 2014). "Hepatitis A in children- clinical course, complications and laboratory profile". Indian J Pediatr. 81 (1): 15–9. doi:10.1007/s12098-013-1114-8. PMID 23904062.
- ↑ Gao LW, Xie ZD, Liu YY, Wang Y, Shen KL (February 2011). "Epidemiologic and clinical characteristics of infectious mononucleosis associated with Epstein-Barr virus infection in children in Beijing, China". World J Pediatr. 7 (1): 45–9. doi:10.1007/s12519-011-0244-1. PMID 21191775.
- ↑ Smiechura M, Strużycka M, Konopka W (2014). "Congenital and acquired cytomegalovirus infection and hearing evaluation in children". Otolaryngol Pol. 68 (6): 303–7. doi:10.1016/j.otpol.2014.04.003. PMID 25308607.
- ↑ Rosche KL, Aljasham AT, Kipfer JN, Piatkowski BT, Konjufca V (2015). "Infection with Salmonella enterica Serovar Typhimurium Leads to Increased Proportions of F4/80+ Red Pulp Macrophages and Decreased Proportions of B and T Lymphocytes in the Spleen". PLoS ONE. 10 (6): e0130092. doi:10.1371/journal.pone.0130092. PMC 4466801. PMID 26068006.
- ↑ Roset MS, Ibañez AE, de Souza Filho JA, Spera JM, Minatel L, Oliveira SC, Giambartolomei GH, Cassataro J, Briones G (2014). "Brucella cyclic β-1,2-glucan plays a critical role in the induction of splenomegaly in mice". PLoS ONE. 9 (7): e101279. doi:10.1371/journal.pone.0101279. PMC 4077732. PMID 24983999.
- ↑ Chandni R, Chandni R, Chandni R (2016). "Extra pulmonary tuberculosis presenting as fever with massive splenomegaly and pancytopenia". IDCases. 4: 20–2. doi:10.1016/j.idcr.2016.02.005. PMC 4802818. PMID 27051579.
- ↑ Sumbele IU, Bopda OS, Kimbi HK, Ning TR, Nkuo-Akenji T (November 2015). "Influence of Plasmodium gametocyte carriage on the prevalence of fever, splenomegaly and cardiovascular parameters in children less than 15 years in the Mount Cameroon area: cross sectional study". BMC Infect. Dis. 15: 547. doi:10.1186/s12879-015-1290-4. PMC 4661959. PMID 26612502.
- ↑ Pan J, Liu L, Yan YH, Shao ZW, Li Q, Zhou RH (August 2014). "[Application of health education path in advanced schistosomiasis patients with splenomegaly in perioperative period]". Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi (in Chinese). 26 (4): 425–7, 430. PMID 25434143.
- ↑ Oz HS (August 2014). "Novel Synergistic Protective Efficacy of Atovaquone and Diclazuril on Fetal-Maternal Toxoplasmosis". Int J Clin Med. 5 (15): 921–932. PMC 4157831. PMID 25210646.
- ↑ Sayyahfar S, Ansari S, Mohebali M, Behnam B (April 2014). "Visceral leishmaniasis without fever in an 11-month-old infant: a rare clinical feature of Kala-azar". Korean J. Parasitol. 52 (2): 189–91. doi:10.3347/kjp.2014.52.2.189. PMC 4028457. PMID 24850963.
- ↑ Francischetto O, Silva LA, Senna KM, Vasques MR, Barbosa GF, Weksler C, Ramos RG, Golebiovski WF, Lamas Cda C (October 2014). "Healthcare-associated infective endocarditis: a case series in a referral hospital from 2006 to 2011". Arq. Bras. Cardiol. 103 (4): 292–8. PMC 4206359. PMID 25352503.
- ↑ Balakrishnan N, Jawanda JS, Miller MB, Breitschwerdt EB (February 2013). "Bartonella henselae infection in a man with hypergammaglobulinaemia, splenomegaly and polyclonal plasmacytosis". J. Med. Microbiol. 62 (Pt 2): 338–41. doi:10.1099/jmm.0.052134-0. PMID 23118473.
- ↑ Modaresi Esfeh J, Culver D, Plesec T, John B (March 2015). "Clinical presentation and protocol for management of hepatic sarcoidosis". Expert Rev Gastroenterol Hepatol. 9 (3): 349–58. doi:10.1586/17474124.2015.958468. PMID 25473783.
- ↑ Chiong FJ, Loewenthal M, Boyle M, Attia J (December 2015). "Serum sickness-like reaction after influenza vaccination". BMJ Case Rep. 2015. doi:10.1136/bcr-2015-211917. PMC 4691861. PMID 26677148.
- ↑ Yu C, Gershwin ME, Chang C (2014). "Diagnostic criteria for systemic lupus erythematosus: a critical review". J. Autoimmun. 48-49: 10–3. doi:10.1016/j.jaut.2014.01.004. PMID 24461385.
- ↑ Huang T, Liu M, Xu G (January 2014). "Felty's syndrome with hyperthyroidism: a case report and literature review". Int J Rheum Dis. 17 (1): 122–4. doi:10.1111/1756-185X.12117. PMID 24472276.
- ↑ Ayto R, Hughes DA (2013). "Gaucher disease and myeloma". Crit Rev Oncog. 18 (3): 247–68. PMID 23510067.
- ↑ Vanier MT (2013). "Niemann-Pick diseases". Handb Clin Neurol. 113: 1717–21. doi:10.1016/B978-0-444-59565-2.00041-1. PMID 23622394.
- ↑ Czeyda-Pommersheim F, Hwang M, Chen SS, Strollo D, Fuhrman C, Bhalla S (2015). "Amyloidosis: Modern Cross-sectional Imaging". Radiographics. 35 (5): 1381–92. doi:10.1148/rg.2015140179. PMID 26230754.
- ↑ DiCaprio MR, Roberts TT (October 2014). "Diagnosis and management of langerhans cell histiocytosis". J Am Acad Orthop Surg. 22 (10): 643–52. doi:10.5435/JAAOS-22-10-643. PMID 25281259.
- ↑ Filipovich AH, Chandrakasan S (October 2015). "Pathogenesis of Hemophagocytic Lymphohistiocytosis". Hematol. Oncol. Clin. North Am. 29 (5): 895–902. doi:10.1016/j.hoc.2015.06.007. PMID 26461149.
- ↑ Hashimoto K, Kariya S, Onoda T, Ooue T, Yamashita Y, Naka K, Okano M, Nishizaki K (March 2014). "Rosai-Dorfman disease with extranodal involvement". Laryngoscope. 124 (3): 701–4. doi:10.1002/lary.24290. PMID 23818241.
- ↑ Hill QA (October 2015). "Autoimmune hemolytic anemia". Hematology. 20 (9): 553–4. doi:10.1179/1024533215Z.000000000401. PMID 26447931.
- ↑ Gravitz L, Pincock S (November 2014). "Sickle-cell disease". Nature. 515 (7526): S1. doi:10.1038/515S1a. PMID 25390134.
- ↑ Abraham I, Tharmarajah S, MacDonald K (March 2013). "Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors". Expert Opin Drug Saf. 12 (2): 235–46. doi:10.1517/14740338.2013.770472. PMID 23419039.